Phoenix Life Sciences International Receives Government Approval to Produce Botanical Pharmaceutical Products in South Pacific
11 October 2018 - 2:34AM
InvestorsHub NewsWire
Denver, CO -- October 10, 2018 -- Investorshub NewsWire --
Phoenix Life Sciences International Limited (OTCMarkets: MJMD) (“Phoenix
Life”), an international adaptive healthcare solutions company,
today announced that the company has received approval from the
Vanuatu Investment Promotion Authority (VIPA) to establish
operations in the country and manufacture botanical pharmaceutical
products.
The Republic of Vanuatu, an island chain in the South Pacific,
is the target of the company’s first major production center.
Phoenix Life is the first botanical researcher and producer to
receive such approval in this nation. This significant milestone
brings Phoenix Life closer to launching local clinical trials and
production for its botanical pharmaceutical and nutritional
products targeting the treatment of various indications.
“This is a major step for the company and our operations in
Vanuatu,” said Chief Executive Officer of Phoenix Life Martin
Tindall. “With this application approval, we can begin to establish
the necessary resources required to initiate clinical trials and
develop scalable production capacity for our botanical
pharmaceutical medications and begin leading the global health
initiative to end the diabetes epidemic.”
According to a new research study published by Global Market Insights,
Inc., the U.S. medical marijuana market is poised to
surpass $8 billion by 2024. According to the same study, that’s a
60% contrast to the $5 billion that the medical marijuana market
was valued at in 2016.
Phoenix Life aims to improve overall international health while
reducing the cost of providing medical services and treatments. The
company plans to partner with the single-payer healthcare systems
in established and emerging economies in order to bring botanical
pharmaceuticals to market.
“In the coming weeks, we anticipate many more substantive
business updates and announcements on how we are continuing our
expansion and are creating change,” continued Tindall. “It’s very
nice to have the support of this governing body and we look forward
to the support of other government agencies in Vanuatu, and in
other countries to follow.”
For more information about Phoenix Life, please visit https://www.plsi.co/.
About Phoenix Life Sciences International
Limited
Phoenix Life Sciences International Limited (OTCMarkets: MJMD) is an adaptive
healthcare solutions company. Our business is to advance research
and integrate programs and manufacturing of products that target
and treat diabetes, pain, cancer, and address psychological,
gastrointestinal, autoimmune, neurological and sleep disorders. We
strive to create partnerships and integrate these programs for
human health into communities worldwide as part of our Global
Health Initiative.
FORWARD-LOOKING STATEMENTS
Information contained in this press release regarding
Phoenix Life Sciences International, Limited and its subsidiaries,
(the “Companies”) may constitute forward-looking statements or
statements which may be deemed or construed to be forward-looking
statements. The words “plan”, “forecast”, “anticipates”,
“estimate”, “project”, “intend”, “expect”, “should”, “believe,” and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements involve, and are
subject to, known and unknown risks, uncertainties and other
factors which could cause the Company’s actual results, performance
(financial or operating) or achievements to differ from the future
results, performance (financial or operating) or achievements
expressed or implied by such forward-looking statements. The risks,
uncertainties and other factors are more fully discussed in the
Company’s filings with the U.S. Securities and Exchange Commission.
All forward-looking statements attributable to the Companies herein
are expressly qualified in their entirety by the above-mentioned
cautionary statement. The Companies disclaim any obligation to
update forward-looking statements contained in this press release,
except as may be required by law.
FOOD AND DRUG ADMINISTRATION (FDA)
DISCLOSURE
These statements have not been evaluated by the FDA and
therefore the products sold by Phoenix Life Sciences International
are not available on U.S. markets.
LEGAL DISCLOSURE
Phoenix Life Sciences International does not sell or distribute
any products in the United States that are in violation of the
United States Controlled Substances Act (US.CSA). This company does
not grow, sell, and distribute cannabis-based products in the
United States and is solely involved with the legal distribution of
medical cannabis products within certain international markets
outside of the United States.
Investor Contact:
Phone: 1.888.717.5655 or international +1.720.699.7222
E-mail: investor.relations@phoenixlife.co
Media Contact:
Kathryn Reinhardt
CMW Media
Kathryn@cmwmedia.com
619-972-3089
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From Apr 2024 to May 2024
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From May 2023 to May 2024